Zydus gets USFDA approval to produce its generic prostate cancer drug

Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer

Bs_logoZydus Lifesciences, Zydus
Photo: X@ZydusUniverse
Press Trust of India New Delhi
2 min read Last Updated : Sep 28 2024 | 6:36 PM IST

Zydus Lifesciences on Saturday said it has received approval from the US health regulator to produce generic prostate cancer treatment drug.

The company has received approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide capsules (40 mg), it said in a regulatory filing.

Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer.

The drug will be produced at the group's manufacturing site in Moraiya, Ahmedabad, Zydus said.

As per IQVIA MAT July 2024 data, Enzalutamide capsules (40 mg) had annual sales of USD 869.4 million in the US.

The group now has 400 approvals and has filed over 465 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Biocon gets 4 observations from USFDA for Bengaluru API facility

Biocon on Saturday said the US health regulator has issued four observations after inspecting its Bengaluru-based API (active pharmaceutical ingredient) facility.

The US Food and Drug Administration (USFDA) conducted a surveillance inspection of the API facility (Site 2), located at Bengaluru from September 23- 27, 2024, the company said in a regulatory filing.

"Four observations were cited at the end of the inspection, which the company will be addressing within the stipulated time," it added.

The company does not foresee any impact on the business, Biocon said.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

You’ve reached your limit of 5 free articles this month.
Subscribe now for unlimited access.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories

  • Over 30 subscriber-only stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Zydus LifesciencesUSFDABiocon

First Published: Sep 28 2024 | 6:36 PM IST